CNS drugs · 2026
Cognitive Effects of Cenobamate as Compared to Perampanel: A Cross-Sectional Multicentre Study in 600 Patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Witt Juri-Alexander, Catalán-Aguilar Judit, Schütz Elisa, von Wrede Randi, Hampel Kevin G, Novitskaya Yulia, Surges Rainer, Garcés Mercedes, Metternich Birgitta, Wagner Kathrin, Villanueva Vicente, Helmstaedter Christoph
Аннотация
BACKGROUND: To date, no study has evaluated the objective cognitive effects of cenobamate (CNB) using an independent comparator group.
OBJECTIVE: To compare cognitive performance in individuals with epilepsy treated with CNB versus perampanel (PER), an antiseizure medication (ASM) without systematic negative effects on objective cognitive performance.
METHODS: This retrospective cross-sectional multicentre study provides a comparative analysis of cognitive performance in patients with epilepsy treated with CNB versus PER. The cognitive assessment focused on executive functions (EpiTrack®). A Bayesian analysis of variance (ANOVA) was conducted to evaluate cognitive performance with treatment type and number of concomitant ASMs as fixed factors.
RESULTS: The analysis included 600 individuals with epilepsy (mean age: 38.7 ± 12.9 years, 48.5% women), 200 of them with CNB (mean dose: 190.9 ± 94.1 mg/day; range 12.5-450.0) and a matched sample (sex, age, age at epilepsy onset, education) of 400 patients with PER (mean dose: 7.1 ± 3.0 mg/day; range 2.0-12.0). ANOVA indicated no difference in cognitive performance between patients treated with CNB versus PER (Bayes Factor [BF] = 0.207) but decisive evidence of a negative effect of more concomitant ASMs (BF = 9.5 × 106).
CONCLUSION: The study demonstrated comparable performance in executive functions in individuals treated with CNB or PER and confirmed the adverse effect of an increasing number of combined ASMs. This appears consistent with previous studies showing mostly stable performance after introduction of CNB. Our study was not suited to address previously claimed dose-dependent cognitive side effects and did not assess episodic memory.
OBJECTIVE: To compare cognitive performance in individuals with epilepsy treated with CNB versus perampanel (PER), an antiseizure medication (ASM) without systematic negative effects on objective cognitive performance.
METHODS: This retrospective cross-sectional multicentre study provides a comparative analysis of cognitive performance in patients with epilepsy treated with CNB versus PER. The cognitive assessment focused on executive functions (EpiTrack®). A Bayesian analysis of variance (ANOVA) was conducted to evaluate cognitive performance with treatment type and number of concomitant ASMs as fixed factors.
RESULTS: The analysis included 600 individuals with epilepsy (mean age: 38.7 ± 12.9 years, 48.5% women), 200 of them with CNB (mean dose: 190.9 ± 94.1 mg/day; range 12.5-450.0) and a matched sample (sex, age, age at epilepsy onset, education) of 400 patients with PER (mean dose: 7.1 ± 3.0 mg/day; range 2.0-12.0). ANOVA indicated no difference in cognitive performance between patients treated with CNB versus PER (Bayes Factor [BF] = 0.207) but decisive evidence of a negative effect of more concomitant ASMs (BF = 9.5 × 106).
CONCLUSION: The study demonstrated comparable performance in executive functions in individuals treated with CNB or PER and confirmed the adverse effect of an increasing number of combined ASMs. This appears consistent with previous studies showing mostly stable performance after introduction of CNB. Our study was not suited to address previously claimed dose-dependent cognitive side effects and did not assess episodic memory.